title: Hemodynamic effects of lactotripeptides from casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: a randomized, double-blind, crossover clinical trial.
abstract: Contrasting data partially support a certain antihypertensive efficacy of lactotripeptides derived from enzymatic treatment of casein hydrolysate. We carried out a randomized, double-blind, crossover clinical study to investigate the antihypertensive efficacy of a short-term treatment with lactotripeptides in Mediterranean subjects with normal or high-normal blood pressure (BP). We consecutively enrolled 55 untreated subjects (men:women = 30:25), 40.3 ± 9.8 years old, with normal or high-normal BP. After 4 weeks of dietary standardization, they were allocated to treatment with a fruit juice containing 3 mg of added Ile-Pro-Pro/Val-Pro-Pro lactotripeptides or with placebo for 4 weeks. After a 4-week washout period, they were then assigned to the alternative treatment for a further period of 4 weeks. Overall, no significant difference has been observed in office BP comparing baseline data with those posttreatment. Repeating the analysis by basal BP level, a mild but significant reduction in systolic BP (-1.7 ± 2.3 mm Hg; t = 3.5, P = .002) has been observed only in subjects with high-normal BP after treatment with lactotripeptides. With regard to 24-hour BP measurement, after lactotripeptide treatment only, the subjects experienced a significant reduction in diurnal diastolic BP (-1.6 ± 5.4 mm Hg; P = .042), diurnal mean BP (-2.1 ± 5.9 mm Hg; P = .19), and 24-hour (-5.4 ± 14.2 mm Hg; P = .011) and diurnal (-7.1 ± 19.2%; P = .014) diastolic BP value measurements relative to normal values. No modification has been observed in relation to plasma renin activity and aldosteronemia. In conclusion, diurnal diastolic BP is significantly reduced by lactrotripeptide supplementation in untreated Mediterranean subjects with normal or high-normal BP. Office systolic BP is reduced only in subjects with high-normal BP.
authors.affiliation: Hypertension Research Unit, Sant'Orsola-Malpighi University Hospital, Bologna, Italy. afgcicero@cardionet.it
authors.forename: Arrigo F G
authors.initials: AF
authors.lastname: Cicero
authors.forename: Martina
authors.initials: M
authors.lastname: Rosticci
authors.forename: Maddalena
authors.initials: M
authors.lastname: Veronesi
authors.forename: Stefano
authors.initials: S
authors.lastname: Bacchelli
authors.forename: Enrico
authors.initials: E
authors.lastname: Strocchi
authors.forename: Camilla
authors.initials: C
authors.lastname: Melegari
authors.forename: Elisa
authors.initials: E
authors.lastname: Grandi
authors.forename: Claudio
authors.initials: C
authors.lastname: Borghi
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure; D018660:Blood Pressure Monitoring, Ambulatory; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002364:Caseins / Q000737:chemistry; D002940:Circadian Rhythm; D018592:Cross-Over Studies; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006439:Hemodynamics; D006801:Humans; D006973:Hypertension / Q000178:diet therapy*; D008297:Male; D019083:Mediterranean Region; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage*; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D002364:Caseins; D009842:Oligopeptides; C489032:isoleucyl-prolyl-proline; C489031:valyl-prolyl-proline; C475729:casein hydrolysate